Arvinas presented new Phase 1 oculomotor and biomarker data for its experimental PROTAC LRRK2 degrader in Parkinson’s disease, marking an early clinical step for targeted protein degradation in neurodegenerative disorders.
published
Arvinas presented new Phase 1 oculomotor and biomarker data for its experimental PROTAC LRRK2 degrader in Parkinson’s disease, marking an early clinical step for targeted protein degradation in neurodegenerative disorders.
Latest documented BWB result
See Billy's timestamped results and follow-through.
Review the latest gains posts, original timestamps, and proof images published by Banking With Billy.
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.